Please assess the completion status of the following clinical trial:

Trial Title: Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic HCV infected genotype 1, 2 (Taiwan only), 4, 5, or 6 male and nonpregnant/ nonlactating females aged 18 years or older who are on dialysis for ESRD, including adults with HIV coinfection if they are suppressed on a stable, protocol-approved antiretroviral (ARV) regimens for ≥8 weeks prior to screening.~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF for 8 weeks (Type: EXPERIMENTAL): Treatment-naive participants with genotype 1 without cirrhosis will receive LDV/SOF for 8 weeks
- LDV/SOF for 12 weeks (Type: EXPERIMENTAL): Treatment-experienced participants with genotype 1 and treatment-naive or treatment-experienced participants with genotype 2 (Taiwan only), 4, 5 and 6 without cirrhosis will receive LDV/SOF for 12 weeks
- LDV/SOF for 24 weeks (Type: EXPERIMENTAL): Participants with compensated cirrhosis will receive LDV/SOF for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).